98%
921
2 minutes
20
The UK Antimicrobial Registry (UKAR) has been developed to capture data on real world usage of antimicrobial agents with an initial focus on those used to treat drug-resistant infections. Several industry partners have committed support for the study, which is included in the National Institute for Health and Care Research (NIHR) portfolio in England with similar arrangements in the three devolved UK nations. The two antimicrobials in the National Institute for Health and Care Excellence (NICE) subscription model pilot (cefiderocol and ceftazidime/avibactam) are included in the UKAR and future expansion of work in this area is planned. This model decouples payment from usage by using a fixed annual fee. The study will provide information on the characteristics of patients receiving study drugs, the infections being treated, treatment effectiveness and adverse events. UKAR potentially provides a novel resource of enduring value to support healthcare in the UK and more widely and contribute to AMR National Action Plan goals for optimal use of antimicrobials.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11258557 | PMC |
http://dx.doi.org/10.1093/jacamr/dlae107 | DOI Listing |
PLoS One
September 2025
Bone Joint and Related Tissues Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: Surgical site infection (SSI) is associated with a significant burden in orthopedic surgeries, leading to increased morbidity, prolonged hospital stays, and higher healthcare costs. Despite the widespread use of prophylactic antibiotics to reduce the risk of infection, the optimal duration for antibiotic administration remains controversial. Newer studies reported controversial results compared to existing guidelines; therefore, we aimed to compare the efficacy and post-operative complications of short-term (<24 hours) and extended oral antibiotics in reducing infection rates following orthopedic surgeries.
View Article and Find Full Text PDFEuro Surveill
September 2025
Welfare Epidemiology and Monitoring Unit, Department of Public Health, Finnish Institute for Health and Welfare, Helsinki, Finland.
BACKGROUNDHerpes zoster, also known as shingles, is a painful skin condition caused by varicella zoster virus. Information is lacking on incidence of herpes zoster in Finland.AIMTo estimate age-specific annual incidence of herpes zoster over 9 years with data from several nationwide health registers.
View Article and Find Full Text PDFHelicobacter
September 2025
Department of Gastroenterology, Peking University Third Hospital, Beijing, China.
Background: The optimal duration for vonoprazan and amoxicillin dual therapy (VA-DT) remains unclear, and studies on gastric acid suppression of vonoprazan during eradication are still lacking.
Objective: This study conducted a multicenter, randomized controlled trial to compare the eradication efficacy between 10 and 14-day VA-DT, and to identify the dynamic changes of gastric pH during treatment.
Methods: This study included 418 naïve adult patients with Helicobacter pylori infection, who were randomly divided into 10 or 14-day VA-DT groups (vonoprazan 20 mg twice daily and amoxicillin 1000 mg thrice daily).
Photodermatol Photoimmunol Photomed
September 2025
Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Background: Cyclosporine is currently recommended as a third-line therapy for chronic spontaneous urticaria (CSU), while narrowband ultraviolet B (NB-UVB) phototherapy has shown promise.
Objective: To compare the efficacy and safety of NB-UVB phototherapy versus cyclosporine in antihistamine-refractory CSU.
Methods: This randomized, prospective, non-inferiority study recruited 50 patients with antihistamine-refractory CSU.
Trials
September 2025
Department of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Kamakura, 247-8533, Japan.
Background: Acute cholangitis (AC) frequently presents as a community-acquired infection and is associated with a high prevalence of antibiotic use among infectious diseases. The Tokyo Guidelines 2018 (TG18) recommend 4-7 days of antibiotic administration after biliary drainage. However, this recommendation lacks strong evidence of its effectiveness and is primarily based on heterogeneous clinical findings and expert opinions.
View Article and Find Full Text PDF